MedPath

Taurine

Generic Name
Taurine
Brand Names
Aminosyn-PF 7%, Premasol, Primene, Trophamine 10 %
Drug Type
Small Molecule
Chemical Formula
C2H7NO3S
CAS Number
107-35-7
Unique Ingredient Identifier
1EQV5MLY3D
Background

Taurine, whose chemical name is 2-aminoethanesulfonic acid, is one of the most abundant amino acids in several organs. It plays important role in essential biological processes. This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.

Indication

The use of diet supplements containing taurine is indicated for the nutritional support of infants and young pediatric patients requiring total parenteral nutrition via central or peripheral routes. The usage of diet supplements containing taurine prevents nitrogen and weight loss or to treat negative nitrogen balance in pediatric patients where the alimentary tract cannot be done through oral, gastrostomy or jejunostomy administration, there is impaired gastrointestinal absorption or protein requirements are substantially increased.

Associated Therapies
Total parenteral nutrition therapy

Thiogenesis Launches Phase 2 Trial of TTI-0102 for MELAS, a Rare Mitochondrial Disease

• Thiogenesis Therapeutics has dosed the first two patients in its Phase 2 clinical trial of TTI-0102 for MELAS, a rare inherited mitochondrial disease with no approved treatments in the EU or US. • The randomized, double-blind, placebo-controlled trial will enroll 12 patients across centers in the Netherlands and France, with endpoints including walking ability, fatigue severity, and quality of life. • TTI-0102 is a prodrug designed to increase intracellular levels of glutathione and taurine, both deficient in MELAS patients, potentially addressing the underlying oxidative stress contributing to the disease.

Thiogenesis Receives EMA Clearance to Initiate Phase 2 Trial of TTI-0102 for MELAS

• Thiogenesis Therapeutics has received EMA clearance to begin a Phase 2 clinical trial for TTI-0102 in patients with MELAS. • The Phase 2 trial is a multi-country, randomized, double-blind, placebo-controlled study that will enroll 12 patients in France and the Netherlands. • TTI-0102 is a prodrug designed to increase intracellular levels of glutathione and taurine, which are deficient in MELAS patients. • The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of TTI-0102 over a 6-month period.
© Copyright 2025. All Rights Reserved by MedPath